Vasopressin in vasodilatory and septic shock

Current Opinion in Critical Care

Volumn 13, Issue 4, 2007, Pages 383-391

  Russell, James A ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Norepinephrine; Septic shock; Vasopressin; Vasopressin receptors; Vasopressinase

Indexed keywords

ARGIPRESSIN; NORADRENALIN; STRESS HORMONE;

ANTIDIURESIS; BLOOD PRESSURE; BRADYCARDIA; CLINICAL STUDY; CONTINUOUS INFUSION; DRUG DEFICIENCY; DRUG INFUSION; DRUG MECHANISM; FINGER ISCHEMIA; HEART ARRHYTHMIA; HEART MUSCLE ISCHEMIA; HEART OUTPUT; HEART RATE; HUMAN; HYPONATREMIA; ISCHEMIA; MESENTERY ISCHEMIA; NONHUMAN; PHYSIOLOGY; REVIEW; SEPTIC SHOCK; SIDE EFFECT; SKIN ISCHEMIA; TACHYCARDIA; URINE VOLUME; VASODILATATION;

HUMANS; NOREPINEPHRINE; RECEPTORS, VASOPRESSIN; SHOCK, SEPTIC; VASODILATION; VASOPRESSINS;

EID: 34347383381     PISSN: 10705295     EISSN: 15317072     Source Type: Journal    
DOI: 10.1097/MCC.0b013e328263885e     Document Type: Review

References (62)

1. Landry DW, Levin HR, Gallant EM, et al. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation 1997; 95:1122-1125.
2. Landry DW, Levin HR, Gallant EM, et al. Vasopressin pressor hypersensitivity in vasodilatory septic shock. Crit Care Med 1997; 25:1279-1282.
3. Barrett LK, Singer M, Clapp LH. Vasopressin: mechanisms of action on the vasculature in health and in septic shock. Crit Care Med 2007; 35:33-40. This is a strong review of mechanisms of action and adverse effects of vasopressin.
4. Dunser MW, Hasibeder WR. Vasopressin in vasodilatory shock: ensure organ blood flow, but take care of the heart! Crit Care 2006; 10:172.
5. Dunser MW, Lindner KH, Wenzel V. A century of arginine vasopressin research leading to new therapeutic strategies. Anesthesiology 2006; 105:444-445. This is a comprehensive review of vasopressin.
6. Dunser MW, Wenzel V, Hasibeder WR. Ischemic skin lesions and microcirculatory collapse during vasopressin therapy: a possible role of the microcirculation? Acta Anaesthesiol Scand 2006; 50:637-638. This highlights potential adverse effects of vasopressin.
7. Dunser MW, Lindner KH, Wenzel V. Vasopressin: multitalented hormone among the shock hormones? Crit Care Med 2006; 34:562-564.
8. Russell JA. Management of sepsis. N Engl J Med 2006; 355:1699-1713. This is a comprehensive review of sepsis and septic shock by the author.
9. Wakatsuki T, Nakaya Y, Inoue I. Vasopressin modulates K(+)-channel activities of cultured smooth muscle cells from porcine coronary artery. Am J Physiol 1992; 263 (2 Pt 2):H491-H496.
10. Landry DW, Oliver JA. The ATP-sensitive K+ channel mediates hypotension in endotoxemia and hypoxic lactic acidosis in dog. J Clin Invest 1992; 89:2071-2074.
11. Herbertson MJ, Werner HA, Walley KR. Nitric oxide synthase inhibition partially prevents decreased LV contractility during endotoxemia. Am J Physiol Heart Circ Physiol 1996; 270 (6 Pt 2):H1979-H1984.
12. Lopez A, Lorente JA, Steingrub J, et al. Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit Care Med 2004; 32:21-30.
13. Watson D, Grover R, Anzueto A, et al. Cardiovascular effects of the nitric oxide synthase inhibitor NG-methyl-L-arginine hydrochloride (546C88) in patients with septic shock: results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002). Crit Care Med 2004; 32:13-20.
14. Ertmer C, Bone HG, Morelli A, et al. Methylprednisolone reverses vasopressin hyporesponsiveness in ovine endotoxemia. Shock 2007; 27:281-288. This describes an interesting interaction of adrenal and vasopressin axes in an animal model of septic shock.
15. Erfurth EM, Hedner P, Lundin S, Ekman R. Release of prolactin as well as adrenocorticotropin after administration of arginine-vasopressin to healthy men. Horm Metab Res 1996; 28:599-602.
16. Dunser MW, Hasibeder WR, Wenzel V, et al. Endocrinologic response to vasopressin infusion in advanced vasodilatory shock. Crit Care Med 2004; 32:1266-1271.
17. Leite-de-Moraes MC, Touraine P, Kelly PA, et al. Prolactin receptor expression in lymphocytes from patients with hyperprolactinemia or acromegaly. J Endocrinol 1995; 147:353-359.
18. Leite De Moraes MC, Touraine P, Gagnerault MC, et al. Prolactin receptors and the immune system. Ann Endocrinol (Paris) 1995; 56:567-570.
19. Zhu XH, Zellweger R, Wichmann MW, et al. Effects of prolactin and metoclopramide on macrophage cytokine gene expression in late sepsis. Cytokine 1997; 9:437-446.
20. Zellweger R, Wichmann MW, Ayala A, et al. Females in proestrus state maintain splenic immune functions and tolerate sepsis better than males. Crit Care Med 1997; 25:106-110.
21. Blanco JD, Gibbs RS, Castaneda YS. Bacteremia in obstetrics: clinical course. Obstet Gynecol 1981; 58:621-625.
22. Patel BM, Chittock DR, Russell JA, Walley KR. Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology 2002; 96:576-582.
23. Sharshar T, Carlier R, Blanchard A, et al. Depletion of neurohypophyseal content of vasopressin in septic shock. Crit Care Med 2002; 30:497-500.
24. Tsuneyoshi I, Yamada H, Kakihana Y, et al. Hemodynamic and metabolic effects of low-dose vasopressin infusions in vasodilatory septic shock. Crit Care Med 2001; 29:487-493.
25. Carnio EC, Stabile AM, Batalhao ME, et al. Vasopressin release during endotoxaemic shock in mice lacking inducible nitric oxide synthase. Pflugers Arch 2005; 450:390-394.
26. Dunser MW, Werner ER, Wenzel V, et al. Arginine vasopressin and serum nitrite/nitrate concentrations in advanced vasodilatory shock. Acta Anaesthesiol Scand 2004; 48:814-819.
27. Lin IY, Ma HP, Lin AC, et al. Low plasma vasopressin/ norepinephrine ratio predicts septic shock. Am J Emerg Med 2005; 23:718-724.
28. Muller B, Morgenthaler N, Stolz D, et al. Circulating levels of copeptin, a novel biomarker, in lower respiratory tract infections. Eur J Clin Invest 2007; 37:145-152.
29. Jochberger S, Morgenthaler NG, Mayr VD, et al. Copeptin and arginine vasopressin concentrations in critically ill patients. J Clin Endocrinol Metab 2006; 91:4381-4386. Copeptin measurements have emerged as another way to assess vasopressin levels indirectly. Copeptin is more stable and easier to measure than vasopressin.
30. Jochberger S, Luckner G, Mayr VD, et al. Course of vasopressin and copeptin plasma concentrations in a patient with severe septic shock. Anaesth Intensive Care 2006; 34:498-500.
31. Jochberger S, Mayr VD, Luckner G, et al. Serum vasopressin concentrations in critically ill patients. Crit Care Med 2006; 34:293-299.
32. Roth BL, Spitzer JA. Altered hepatic vasopressin and alpha 1-adrenergic receptors after chronic endotoxin infusion. Am J Physiol 1987; 252 (5 Pt 1):E699-702.
33. Holmes CL, Walley KR, Chittock DR, et al. The effects of vasopressin on hemodynamics and renal function in severe septic shock: a case series. Intensive Care Med 2001; 27:1416-1421.
34. Dunser MW, Mayr AJ, Ulmer H, et al. The effects of vasopressin on systemic hemodynamics in catecholamine-resistant septic and postcardiotomy shock: a retrospective analysis. Anesth Analg 2001; 93:7-13.
35. Dunser MW, Mayr AJ, Ulmer H, et al. Arginine vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled study. Circulation 2003; 107:2313-2319.
36. Gold JA, Cullinane S, Chen J, et al. Vasopressin as an alternative to norepinephrine in the treatment of milrinone-induced hypotension. Crit Care Med 2000; 28:249-252.
37. Gold J, Cullinane S, Chen J, et al. Vasopressin in the treatment of milrinone-induced hypotension in severe heart failure. Am J Cardiol 2000; 85:506-508; A11.
38. Malay MB, Ashton JL, Dahl K, et al. Heterogeneity of the vasoconstrictor effect of vasopressin in septic shock. Crit Care Med 2004; 32:1327-1331.
39. Morales DL, Gregg D, Helman DN, et al. Arginine vasopressin in the treatment of 50 patients with postcardiotomy vasodilatory shock. Ann Thorac Surg 2000; 69:102-106.
40. Argenziano M, Choudhri AF, Oz MC, et al. A prospective randomized trial of arginine vasopressin in the treatment of vasodilatory shock after left ventricular assist device placement. Circulation 1997; 96 (9 Suppl):II-286-II-290.
41. Argenziano M, Chen JM, Choudhri AF, et al. Management of vasodilatory shock after cardiac surgery: identification of predisposing factors and use of a novel pressor agent. J Thorac Cardiovasc Surg 1998; 116:973-980.
42. Argenziano M, Chen JM, Cullinane S, et al. Arginine vasopressin in the management of vasodilatory hypotension after cardiac transplantation. J Heart Lung Transplant 1999; 18:814-817.
43. Chen JM, Cullinane S, Spanier TB, et al. Vasopressin deficiency and pressor hypersensitivity in hemodynamically unstable organ donors. Circulation 1999; 100 (19 Suppl):II244-II246.
44. Rosenzweig EB, Starc TJ, Chen JM, et al. Intravenous arginine-vasopressin in children with vasodilatory shock after cardiac surgery. Circulation 1999; 100 (19 Suppl):II182-II186.
45. Malay MB, Ashton RC Jr, Landry DW, Townsend RN. Low-dose vasopressin in the treatment of vasodilatory septic shock. J Trauma 1999; 47:699-703.
46. Dunser MW, Mayr AJ, Stallinger A, et al. Cardiac performance during vasopressin infusion in postcardiotomy shock. Intensive Care Med 2002; 28:746-751.
47. Holmes CL, Russell JA. Plasmafiltration in sepsis: removing the evil humors. Crit Care Med 1999; 27:2287-2289.
48. Lauzier F, Levy B, Lamarre P, Lesur O. Vasopressin or norepinephrine in early hyperdynamic septic shock: a randomized clinical trial. Intensive Care Med 2006; 32:1782-1789. This is another recent proof of principle study of vasopressin in septic shock.
49. Hayes MA, Timmins AC, Yau EH, et al. Elevation of systemic oxygen delivery in the treatment of critically ill patients. N Engl J Med 1994; 330:1717-1722.
50. Bomzon L, Rosendorff C. Renovascular resistance and noradrenaline. Am J Physiol 1975; 229:1649-1653.
51. Martin C, Papazian L, Perrin G, et al. Norepinephrine or dopamine for the treatment of hyperdynamic septic shock? Chest 1993; 103:1826-1831.
52. Martikainen TJ, Tenhunen JJ, Uusaro A, Ruokonen E. The effects of vasopressin on systemic and splanchnic hemodynamics and metabolism in endotoxin shock. Anesth Analg 2003; 97:1756-1763.
53. Klinzing S, Simon M, Reinhart K, et al. High-dose vasopressin is not superior to norepinephrine in septic shock. Crit Care Med 2003; 31:2646-2650.
54. van Haren FM, Rozendaal FW, van der Hoeven JG. The effect of vasopressin on gastric perfusion in catecholamine-dependent patients in septic shock. Chest 2003; 124:2256-2260.
55. Dunser MW, Mayr AJ, Tur A, et al. Ischemic skin lesions as a complication of continuous vasopressin infusion in catecholamine-resistant vasodilatory shock: incidence and risk factors. Crit Care Med 2003; 31:1394-1398.
56. Kaufmann JE, Oksche A, Wollheim CB, et al. Vasopressin-induced von Willebrand factor secretion from endothelial cells involves V2 receptors and cAMP. J Clin Invest 2000; 106:107-116.
57. Mannucci PM, Ruggeri ZM, Pareti FI, Capitanio A. D.D.A.V.P. in haemophilia. Lancet 1977; 2:1171-1172.
58. Mannucci PM, Ruggeri ZM, Pareti FI, Capitanio A. 1-Deamino-8-d-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrands' diseases. Lancet 1977; 1:869-872.
59. Lolait SJ, O'Carroll AM, McBride OW, et al. Cloning and characterization of a vasopressin V2 receptor and possible link to nephrogenic diabetes insipidus. Nature 1992; 357:336-339.
60. Reiter RA, Knobl P, Varadi K, Turecek PL. Changes in von Willebrand factor-cleaving protease (ADAMTS13) activity after infusion of desmopressin. Blood 2003; 101:946-948.
61. Michiels JJ, van de Velde A, van Vliet HH, et al. Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications. Semin Thromb Hemost 2002; 28:111-132.
62. Dellinger RP, Carlet JM, Masur H, et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004; 32:858-873.